[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]

Rev Med Interne. 2021 Jan;42(1):65-66. doi: 10.1016/j.revmed.2020.11.008. Epub 2020 Dec 9.
[Article in French]
No abstract available

Publication types

  • Letter

MeSH terms

  • Albuminuria / drug therapy
  • Benzhydryl Compounds / therapeutic use
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / epidemiology
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucosides / therapeutic use
  • Humans
  • Kidney
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / drug therapy

Substances

  • Benzhydryl Compounds
  • Glucosides
  • dapagliflozin